COMy 2021 | CAR-T therapy vs. ASCT for myeloma
Arnon Nagler
• 10 May 2021
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses whether autologous stem cell transplant (ASCT) is still necessary with the recent successes of CAR-T therapy. In some countries (such as the US), there has been a recent reduction in the number of myeloma patients having ASCT. Prof. Nagler suggests that this is partly due to the rise of CAR-T, as well as novel agents. However, due to the high cost of CAR-T therapy many countries will continue to use ASCT for the foreseeable future. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
